rs71625130 — SNX27 1q21.3 T-cell signaling / Th17 locus variant

SNX27 rs71625130 — The T-Cell Synapse Variant at the Heart of Atopic Inflammation

Atopic dermatitis (eczema) is the most common chronic inflammatory skin disease, driven by an immune system that responds inappropriately to harmless environmental triggers. One of its key drivers is T-helper cell dysregulation¹¹ T-helper cell dysregulation
T helper cells coordinate immune responses by releasing cytokines; subtypes Th2, Th17, and Th22 all contribute to eczema flares through different inflammatory signals, particularly an imbalance that tips immune activation too far toward inflammation. The rs71625130 variant sits at a genetic locus — chromosome 1q21.3 — that has emerged as one of the most statistically robust atopic dermatitis risk signals ever identified, with an association p-value of 2×10⁻⁸⁹.

The SNP lies within an intron of SNX27 (Sorting Nexin 27), a scaffolding protein that governs how signalling molecules are trafficked within T cells. The 1q21.3 locus also harbours RORC approximately 150 kb downstream — the gene encoding RORγt²² RORγt
RAR-related orphan receptor gamma-t; the master transcription factor that drives Th17 cell differentiation and IL-17 production — making this a biologically coherent stretch of immune regulation DNA.

The Mechanism

SNX27 operates at the immune synapse³³ immune synapse
The organised interface formed between a T cell and an antigen-presenting cell; SNX27 localises here in an activation-dependent manner to regulate signalling kinetics — the contact zone where T cells recognise foreign antigens and decide whether to mount an immune response. SNX27's PDZ domain physically escorts diacylglycerol kinase ζ (DGKζ)⁴⁴ diacylglycerol kinase ζ (DGKζ)
An enzyme that phosphorylates the second messenger diacylglycerol (DAG), reducing its concentration and dampening downstream TCR signalling through PKC and Ras/ERK pathways back to the membrane. This acts as a tuning mechanism: SNX27 limits how strongly a T cell fires.

Beyond DGKζ recycling, SNX27 directly controls the abundance of Lck and CD4⁵⁵ Lck and CD4
Lck is the tyrosine kinase that phosphorylates the T cell receptor complex; CD4 is the co-receptor that stabilises and amplifies the TCR signal. Together they set the threshold for T cell activation at the cell surface. When SNX27 expression is reduced, CD4 and Lck levels fall in resting T cells, yet paradoxically the cells become hyperresponsive: NF-κB activity rises, CXCR4 is upregulated, and lytic enzymes and proinflammatory cytokines pour out. The result is a T cell that activates too easily and produces too much inflammation.

The intronic rs71625130-A allele most likely acts as a regulatory variant⁶⁶ regulatory variant
A non-coding change that alters how much SNX27 is made in immune cells, rather than changing the protein sequence itself; eQTL databases show expression-level effects at this locus, reducing SNX27 expression in T cells and thereby lowering the threshold for inflammatory T cell activation. The nearby RORC gene, whose protein product drives Th17 cell differentiation⁷⁷ Th17 cell differentiation
Th17 cells produce IL-17A, IL-17F, and IL-22, cytokines that trigger epidermal barrier disruption and neutrophil recruitment; RORC is the transcription factor that commits naïve T cells to the Th17 fate, shares long-range regulatory elements at 1q21.3 and may be co-regulated with SNX27 in immune tissue contexts.

The Evidence

The key evidence comes from the largest atopic dermatitis GWAS conducted to date. Budu-Aggrey et al. 2023⁸⁸ Budu-Aggrey et al. 2023
European and multi-ancestry genome-wide association meta-analysis; discovery cohort 1,086,394 individuals; replication cohort 3,604,027 individuals — by far the largest AD genetic study identified 81 loci in Europeans (29 novel) and 10 additional multi-ancestry loci, with rs71625130-A emerging as one of the strongest signals at OR=1.17 and an extraordinary p-value of 2×10⁻⁸⁹. The A allele frequency of ~4% in Europeans means it is carried heterozygously by roughly 1 in 15 Europeans — a meaningful population burden for such a strong effect.

The biological plausibility rests on independent functional studies. Martinez-Martin et al. 2024⁹⁹ Martinez-Martin et al. 2024
Nat Commun; demonstrated SNX27 regulation of Lck/CD4 at the T cell immune synapse and downstream proinflammatory consequences of SNX27 loss showed that impaired SNX27 expression contributes directly to CD4 T cell dysfunction with inflammatory features consistent with atopic disease. Cosen-Binker et al. 2017¹⁰¹⁰ Cosen-Binker et al. 2017
J Immunol; showed SNX27-DGKζ axis controls TCR signalling amplitude and T cell metabolic programming established the mechanistic link between SNX27, signal calibration, and the transcriptional programmes that determine whether a T cell triggers inflammation. Together these studies support rs71625130-A as a functional eQTL that biases the 1q21.3 locus toward lower SNX27 expression, hyperactivated T cells, and elevated atopic inflammation.

The shared genetics of the IL-23/Th17 axis across atopic dermatitis, psoriasis, inflammatory bowel disease, and ankylosing spondylitis — diseases all amenable to IL-17 or IL-23 blockade¹¹¹¹ IL-17 or IL-23 blockade
Biologic therapies targeting IL-17A (secukinumab, ixekizumab) or IL-23p19 (guselkumab, risankizumab) are approved across psoriasis, PsA, IBD, and AS, validating the Th17 axis as a genuine shared therapeutic target — adds strong contextual plausibility to the 1q21.3 locus as a genuine autoimmune-axis risk region.

Practical Actions

Carriers of the A allele have a modestly elevated baseline tendency toward Th17-axis overactivation. This translates to increased lifetime susceptibility to atopic dermatitis and possibly other Th17-mediated conditions. The variant's effect is additive, so heterozygous carriers (AG) have one dose of risk and homozygous carriers (AA) — extremely rare, under 0.05% — carry two.

Monitoring atopic disease activity and considering the triggers that amplify Th17 responses (gut dysbiosis, vitamin D insufficiency, prolonged stress) is relevant for carriers. The same IL-23/Th17 pathway that underlies this SNP is the therapeutic target of dupilumab and several approved biologics, meaning carriers who develop moderate-to-severe AD have access to precisely targeted therapies.

Interactions

The 1q21.3 locus acts within the broader IL-23/Th17 immune axis. Variants in IL23R (rs11209026), IL12B, and TYK2 that modulate this same signalling cascade are documented co-risk loci across atopic disease. Carriers of rs71625130-A who also carry risk variants in barrier genes (FLG, SPINK5) face a dual insult: impaired skin barrier combined with a hyperactivated Th17 immune response, which is the classic setup for severe, early-onset atopic dermatitis.